Curaleaf Holdings (CURLF) Non-Current Deferred Tax Liability (2019 - 2026)
Curaleaf Holdings (CURLF) posted quarterly Non-Current Deferred Tax Liability of $212.0 million for Q4 2025, down 13.39% year-over-year from $244.8 million in Q4 2024, and down 13.39% quarter-over-quarter from $244.8 million in Q4 2024.
Curaleaf Holdings (CURLF) Non-Current Deferred Tax Liability (2019 - 2026) Analysis & Trends
Curaleaf Holdings' Non-Current Deferred Tax Liability history runs 7 years deep, the most recent figure standing at $212.0 million for Q4 2025.
- In Q4 2025, Non-Current Deferred Tax Liability fell 13.39% year-over-year to $212.0 million; the TTM figure through Dec 2025 stood at $212.0 million (down 13.39% YoY), while the FY2025 annual figure was $212.0 million, down 13.39% from the prior year.
- Non-Current Deferred Tax Liability for Q4 2025 stood at $212.0 million, down from $244.8 million in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $342.6 billion in Q1 2022, with the low at $212.0 million in Q4 2025.
- The 5-year median for Non-Current Deferred Tax Liability is $300.3 million (2021), against an average of $24.7 billion.
- The sharpest annual moves came in 2022 and 2024: Non-Current Deferred Tax Liability surged 153837.26% in 2022, then slipped 17.64% in 2024.
- Curaleaf Holdings' Non-Current Deferred Tax Liability stood at $257.8 million in 2021, then gained by 28.91% to $332.3 million in 2022, then decreased by 10.57% to $297.2 million in 2023, then fell by 17.64% to $244.8 million in 2024, then declined by 13.39% to $212.0 million in 2025.
- Business Quant data shows CURLF's Non-Current Deferred Tax Liability at $212.0 million in Q4 2025, $244.8 million in Q4 2024, and $276.2 million in Q3 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - |
| 10 | Curaleaf Holdings | 2.48 Bn | 2.38 Bn | 169.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 129.22 Mn |
| Jun 30, 2026 | 129.22 Mn |
| Dec 31, 2025 | 212.00 Mn |
| Dec 31, 2025 | 212.00 Mn |
| Dec 31, 2024 | 244.77 Mn |
| Dec 31, 2024 | 244.77 Mn |
| Sep 30, 2024 | 276.22 Mn |
| Sep 30, 2024 | 276.22 Mn |
| Jun 30, 2024 | 285.59 Mn |
| Jun 30, 2024 | 285.59 Mn |
| Dec 31, 2023 | 297.19 Mn |
| Dec 31, 2023 | 297.19 Mn |
| Sep 30, 2023 | 311.04 Mn |
| Sep 30, 2023 | 311.04 Mn |
| Jun 30, 2023 | 318.21 Mn |
| Jun 30, 2023 | 318.21 Mn |
| Sep 30, 2022 | 332.31 Mn |
| Sep 30, 2022 | 332.31 Mn |
| Jun 30, 2022 | 334.81 Mn |
| Jun 30, 2022 | 334.81 Mn |